UBS analyst Colin Bristow raised the firm’s price target on Eli Lilly to $447 from $438 and keeps a Buy rating on the shares. Eli Lilly reported a "solid" Mounjaro beat and UBS sees a good setup through 2023, though Alzheimer’s remains a risk, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- Eli Lilly price target raised to $440 from $375 at Wells Fargo
- Investors Cheer Eli Lilly’s Obesity Drug Update, Ignore Weak Earnings
- Nektar to regain full rights to Rezpegaldesleukin from Eli Lilly
- Zura Bio announces ZB-106 license from Eli Lilly
- Eli Lilly raises FY23 adjusted EPS view to $8.65-$8.85 from $8.35-$8.55
